0001181431-13-030119.txt : 20130523 0001181431-13-030119.hdr.sgml : 20130523 20130523152854 ACCESSION NUMBER: 0001181431-13-030119 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130517 FILED AS OF DATE: 20130523 DATE AS OF CHANGE: 20130523 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Florence Anthony A. Jr. CENTRAL INDEX KEY: 0001559827 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32715 FILM NUMBER: 13868158 MAIL ADDRESS: STREET 1: 5425 WISCONSIN AVENUE, SUITE 800 CITY: CHEVY CHASE STATE: MD ZIP: 20815 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INTERLEUKIN GENETICS INC CENTRAL INDEX KEY: 0001037649 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 943123681 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 1-781-398-0700 MAIL ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL SCIENCE SYSTEMS INC DATE OF NAME CHANGE: 19971003 3 1 rrd380970.xml X0206 3 2013-05-17 0 0001037649 INTERLEUKIN GENETICS INC ILIU 0001559827 Florence Anthony A. Jr. 5435 WISCONSIN AVENUE SUITE 800 CHEVY CHASE MD 20815 0 0 1 0 Common Stock 15429122 I See Note 1 Common Stock Warrant (right to buy) .2745 Common Stock 11571842 I See Note 1 The Reporting Person is a Director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 is the sole member of Growth Equity Opportunities Fund III, LLC ("GEO") , the direct beneficial owner of the Shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the Shares held by GEO, except to the extent of his pecuniary interest therein. 63% of the warrants are exercisable on 05/17/2013 (the "Initial Exercise Date") and 37% of the warrants are exercisable on the date the Issuer's shareholders approve an increase in the number of authorized shares of common stock under the Issuer's certificate of incorporation. The warrants terminate if they are not exercised on or prior to the close of business on the seven year anniversary of the Initial Exercise Date. /s/ Louis Citron, attorney-in-fact 2013-05-23